JPWO2023174998A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023174998A5
JPWO2023174998A5 JP2024554930A JP2024554930A JPWO2023174998A5 JP WO2023174998 A5 JPWO2023174998 A5 JP WO2023174998A5 JP 2024554930 A JP2024554930 A JP 2024554930A JP 2024554930 A JP2024554930 A JP 2024554930A JP WO2023174998 A5 JPWO2023174998 A5 JP WO2023174998A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
acid sequence
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509648A (ja
JP2025509648A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/056591 external-priority patent/WO2023174998A1/en
Publication of JP2025509648A publication Critical patent/JP2025509648A/ja
Publication of JP2025509648A5 publication Critical patent/JP2025509648A5/ja
Publication of JPWO2023174998A5 publication Critical patent/JPWO2023174998A5/ja
Pending legal-status Critical Current

Links

JP2024554930A 2022-03-16 2023-03-15 腫瘍抗原、腫瘍抗原ｋｒａｓ、ｔｐｘ２又はａｕｒｋａを含む化合物及びそれらの使用 Pending JP2025509648A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22162533 2022-03-16
EP22162533.8 2022-03-16
EP22204783 2022-10-31
EP22204783.9 2022-10-31
PCT/EP2023/056591 WO2023174998A1 (en) 2022-03-16 2023-03-15 Tumor antigens, compounds comprising the tumor antigens kras, tpx2 or aurka and uses thereof

Publications (3)

Publication Number Publication Date
JP2025509648A JP2025509648A (ja) 2025-04-11
JP2025509648A5 JP2025509648A5 (https=) 2025-04-18
JPWO2023174998A5 true JPWO2023174998A5 (https=) 2025-04-18

Family

ID=85601530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554930A Pending JP2025509648A (ja) 2022-03-16 2023-03-15 腫瘍抗原、腫瘍抗原ｋｒａｓ、ｔｐｘ２又はａｕｒｋａを含む化合物及びそれらの使用

Country Status (17)

Country Link
US (1) US20240033336A1 (https=)
EP (1) EP4493209A1 (https=)
JP (1) JP2025509648A (https=)
KR (1) KR20240161969A (https=)
AR (1) AR128799A1 (https=)
AU (1) AU2023235401A1 (https=)
CA (1) CA3252229A1 (https=)
CL (1) CL2024002708A1 (https=)
CO (1) CO2024012166A2 (https=)
CR (1) CR20240374A (https=)
DO (1) DOP2024000166A (https=)
IL (1) IL315096A (https=)
JO (1) JOP20240203A1 (https=)
MX (1) MX2024011238A (https=)
PE (1) PE20242221A1 (https=)
TW (1) TW202346363A (https=)
WO (1) WO2023174998A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118256561A (zh) * 2024-03-22 2024-06-28 徐州医科大学 靶向双激酶aurka/cdk7的疫苗在治疗实体瘤中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2291071B1 (es) 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
DE102008050860A1 (de) 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
US20120237535A1 (en) 2009-09-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Therapeutic Compositions For The Treatment of HPV-Induced Diseases
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
WO2014093602A1 (en) * 2012-12-14 2014-06-19 Profectus Biosciences, Inc. Compositions and methods for treating and preventing hepatitis c virus infection
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
DK3515476T3 (da) * 2016-09-21 2024-09-02 Amal Therapeutics Sa Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer
JP2020514321A (ja) * 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors

Similar Documents

Publication Publication Date Title
ES2986021T3 (es) Proteína factor 1 para la utilización en el tratamiento o prevención de enfermedades
JP2021501572A5 (https=)
US20220169701A1 (en) Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer
JP2013513377A5 (https=)
JP2021525549A5 (https=)
US9757473B2 (en) Cell-penetrating peptide and conjugate comprising same
US20250312428A1 (en) Heterologous Prime Boost Vaccine
EP3796891A1 (en) Therapeutic constructs for treating cancer
CN104755619A (zh) 用于预防猪水肿病的疫苗
JPWO2020012485A5 (https=)
WO2020072371A1 (en) Melanoma canine vaccine compositions and methods of use thereof
JPWO2020097393A5 (https=)
KR102166549B1 (ko) 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
JPWO2023174998A5 (https=)
JP2023516089A (ja) がんの治療のための組成物及び方法
JP2020526202A5 (https=)
Lee et al. Multicistronic IVT mRNA for simultaneous expression of multiple fluorescent proteins
US12233135B2 (en) Therapeutic constructs for treating cancer
JPWO2022053703A5 (https=)
WO2024240179A1 (zh) 一种用于激活嵌合抗原受体效应细胞的中间模块分子及其应用
WO2025007890A1 (zh) 新型疫苗递送体系
ES2692389T3 (es) Terapia antitumoral mejorada mediante virus oncolíticos dirigidos a células madre tumorales
CA3133972A1 (en) Methods for inducing an immune response against neoantigens
WO2024026274A2 (en) Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)
JPWO2019227106A5 (https=)